Liver cancer has a more aggressive disease course in HIV-positive people co-infected with viral hepatitis
Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring
Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising
Nucleoside analogues reduce hepatitis B liver cancer risk
Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis
Interferon-free hepatitis C treatment with faldaprevir proves safe and effective in people with cirrhosis
Simeprevir is safe and effective with interferon/ribavirin for hepatitis C patients with cirrhosis
